Does STIM pay a dividend and is it safe?

Neuronetics Inc. (STIM) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Stock Ratings / Health Care / STIM / dividends

PDEX (54) KTWO (56) KRMD (41) UTMD (62) ⌘ Pro Terminal →

Neuronetics Inc. (STIM) Dividend Safety Gauge & 10-Year DRIP Compounder

Q: Where is STIM trading relative to its 50-day, 200-day, and 52-week technical levels?

STIM last traded at $2.06 (-8.44% on volume of 976,157 shares), positioning the stock -17.60% below its 50-day simple moving average ($2.50) and +9.57% above its 200-day simple moving average ($1.88). Across its 52-week range of $0.80 to $3.44, STIM sits at the 47.7% percentile with a 14-day RSI of 49.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.80 to $2.32).

$2.06 -8.44% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.02

Neuronetics Inc. (STIM) carries a Roarable Rating of E (Strong Sell) with 28/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $171.4M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on STIM Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is STIM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Neuronetics Inc. (NASDAQ: STIM) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $2.06 (-8.44% 1D, market cap $171.4M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 6/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, STIM ranks #861 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does STIM compare to PDEX and KTWO in the Health Care sector?

▼

Within the Health Care sector (Medical/Dental Instruments), STIM carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of 48.5%, and ROIC of -35.0%. By comparison, PDEX (Pro-Dex Inc.) holds a D+ grade (54/100 RQD, P/E 22.2x, ROIC 23.2%, cap $186.1M) and KTWO (K2 Capital Acquisition Corporation Class A Ordinary Share) posts a D+ grade (56/100 RQD, P/E N/A, ROIC —, cap $202.2M). Among the 5-stock peer group, PDEX leads on earnings multiple (22.2x) while UTMD leads on capital efficiency (26.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for STIM?

▼

Per STIM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001227636), Neuronetics Inc. generated $149.2M in revenue (+99.2% YoY), -$39.0M in net income, and -$20.4M in free cash flow against $141.6M in total assets and $65.8M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $2.02 (-1.71%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (28/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.0% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-13.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for STIM)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (28/100 Composite)

🔍 WHY STIM SCORES 28/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+9/20 pts (32% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+6/20 pts (21% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 5/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$1.99-0.5% Next Q

Q2 (-2Q)

Grade E$1.98+10.6% Next Q

Q3 (-1Q)

Grade E$2.19-5.9% Next Q

Current

Grade E$2.06-10% Hist 90D α

Trajectory: E (20) → E (28)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a STIM Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While STIM currently carries a cautious 28/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.50) and Max Pain ($2.16) forces dealer call-delta covering toward $3.61.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $STIM• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “STIM Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 28%NO 72%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

0.6% Total Yield

0% Cash ($0.00/yr) + 0.6% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (15.1% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $40,809

Est. Year-10 Shareholder Yield: $245/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$11.5K

Yr 1

$13.2K

Yr 2

$15.2K

Yr 3

$17.6K

Yr 4

$20.2K

Yr 5

$23.3K

Yr 6

$26.8K

Yr 7

$30.8K

Yr 8

$35.5K

Yr 9

$40.8K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring STIM)

✓Walkthrough of STIM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

STIM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +1.98%🛡️ HOLDING TREND SUPPORT

2026-11-03O $2.38H $2.38L $2.06C $2.06VOL 1.09M

RES: $4.01SUP: $1.95SMA50: $2.50SMA200: $1.88

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

STIM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 STIM Butterfly Map → + Track STIM →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. +99.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on STIM today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for STIM. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for STIM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (STIM)

Health Care Rank #861 of 1015 ⚔️ PDEX vs STIM Full Matrix →

1. Head-to-Head Health Care Peer Comparison (STIM vs. PDEX, KTWO, KRMD, UTMD)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Neuronetics Inc. (STIM) ranks #861 by composite RQD confidence (28/100, grade E) and #592 by equity capitalization ($171.4M). Within this direct 5-issuer industry benchmark cohort, PDEX leads on earnings valuation at 22.2x trailing P/E, while UTMD leads on capital efficiency and profitability with 26.9% ROIC and 57.1% gross margin. UTMD currently holds the highest overall quantitative score in the immediate peer group at 62/100 (C) compared with STIM at 28/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
STIM ACTIVE Neuronetics Inc.	E	28/100	—	48.5%	-35.0%	-8.44%	$171.4M	Benchmark Subject
PDEX Pro-Dex Inc.	D+	54/100	22.2x	29.3%	23.2%	-0.88%	$186.1M	/pdex-vs-stim →
KTWO K2 Capital Acquisition Corporation Class A Ordinary Share	D+	56/100	—	—	—	+0.20%	$202.2M	/ktwo-vs-stim →
KRMD KORU Medical Systems Inc.	D-	41/100	—	62.3%	-28.7%	+2.01%	$138.1M	/krmd-vs-stim →
UTMD Utah Medical Products Inc.	C	62/100	—	57.1%	26.9%	+3.64%	$216.7M	/utmd-vs-stim →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001227636 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Neuronetics Inc. (STIM) reported GAAP revenue of $149.2M (+99.2% vs. FY2024 revenue of $74.9M , and +109.1% cumulative change since FY2023) , GAAP net income of -$39.0M, operating cash flow of -$20.4M, and free cash flow of -$20.4M (+34.2% YoY). On the balance sheet, STIM closed FY2025 with $141.6M in total assets against $65.8M in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$149.2M	-$39.0M	-$20.4M	-$20.4M	$141.6M	$65.8M
FY2024 (FY)	2024-12-31	$74.9M	-$43.7M	-$31.0M	-$31.0M	$140.9M	$55.2M
FY2023 (FY)	2023-12-31	$71.3M	-$30.2M	-$32.0M	-$32.0M	—	—

3. STIM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is STIM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does STIM compare to PDEX and KTWO in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for STIM?

Where is STIM trading relative to its 50-day, 200-day, and 52-week technical levels?

STIM last traded at $2.06 (-8.44% on volume of 976,157 shares), positioning the stock -17.60% below its 50-day simple moving average ($2.50) and +9.57% above its 200-day simple moving average ($1.88). Across its 52-week range of $0.80 to $3.44, STIM sits at the 47.7% percentile with a 14-day RSI of 49.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.80 to $2.32).

Direct Sub-Reports: STIM RQD Cockpit STIM 12M Forecast STIM Earnings & Move STIM Dividends & DRIP STIM Insiders & 13F STIM Whale Options STIM Profit Sankey STIM News & Why

ROARABLE RATING BRIEF • RQD 28/100 (E) ✓ SEC XBRL & RQD VERIFIED

STIM — Neuronetics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Neuronetics Inc. (STIM) earns a live Roarable RQD composite score of 28/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $2.06 (-8.44% 1D, market capitalization $171.4M).

Fundamental Cash Engine (5/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 48.5%, operating margin of -21.1%, and free cash flow yield of -11.25%.
Whale 13F & Options Flow (9/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (5/20) + Forensic Balance Sheet (6/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 5/9, and Debt/Equity of 2.94x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Neuronetics Inc. (STIM) is a NASDAQ-listed issuer in the Health Care sector, operating in the Medical/Dental Instruments industry. The profile describes the company as having a market capitalization of $0.2B. FY 2025 revenue was $149.2M.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Neuronetics Inc. (STIM) reported $149.2M in annual revenue (up from $74.9M in FY2024, +99.2% YoY) and -$39.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($71.3M revenue, -$30.2M net income) through FY2025, STIM scaled operating cash flow to -$20.4M and free cash flow to -$20.4M, backed by $141.6M in total assets against $65.8M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (E • RQD 28/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -11.25% and institutional whale pillar of 9/20. With Fundamental Cash Engine at 5/20 and Institutional Whale Flow at 9/20, sustained execution supports upside toward the upper end of the $0.80 – $3.44 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -21.1% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Medical/Dental Instruments (Health Care), STIM carries a macro regime beta of 1.00 and gross margin of 48.5%.

Key Question #1: Can STIM sustain or expand its -21.1% operating margin and -35.0% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $149.2M and free cash flow of -$20.4M, how will capital allocation balance growth reinvestment against $65.8M in total debt?
Key Question #3: How sensitive is STIM's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

STIM Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Neuronetics Inc. (STIM) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to STIM Debate Forum (3) ↓

🟡 MARKET WIRE StockInvest.us • 22h ago

Neuronetics Stock Price Forecast. Should You Buy STIM?

StockInvest.us report covering Neuronetics Inc. (STIM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago

Neuronetics, Inc. (STIM) Seasonal Returns Chart - Yahoo Finance

Yahoo! Finance Canada report covering Neuronetics Inc. (STIM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Seeking Alpha • 1d ago

Neuronetics: Transforming From Device Manufacturer To Psychedelic Infrastructure (STIM)

Seeking Alpha report covering Neuronetics Inc. (STIM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Starling Oncology (STLN) Stock Gets Fair Value Boost On Capitated Revenue And Nexus Views

Yahoo Finance report covering Neuronetics Inc. (STIM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ad-hoc-news.de • 1d ago

Neuronetics schedules November 4 results for Neuronetics stock

ad-hoc-news.de report covering Neuronetics Inc. (STIM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 1d ago

Beta Bionics, Inc. (BBNX) Reports Q3 Loss, Beats Revenue Estimates

Yahoo Finance report covering Neuronetics Inc. (STIM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 13d ago

Neuronetics to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call

MALVERN, Pa., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through the Greenbrook netwo

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 13d ago

Integra LifeSciences (IART) Surpasses Q3 Earnings Estimates

Integra (IART) delivered earnings and revenue surprises of +5.36% and -0.81%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

STIM Bull vs. Bear Conversation Board — What's Your Call at $2.06?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON STIM 🐻 33% BEARISH CONVICTION

MA MacroHawk_NYC RQD DEBATE OPENER • Cross-Asset Macro Desk 🐂 BULLISH 🎯 Target: $2.81 (+24.9%)

📌 Pinned Debate

Whale 13F Flow pillar at 11/20 is the rating's strongest component, reflecting institutional accumulation and options positioning.

Don't sleep on STIM's setup in Health Care. Whale 13F Flow pillar at 11/20 is the rating's strongest component, reflecting institutional accumulation and options positioning.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (28/100) backs up the fundamental quality.

EarningsSniper 🐂 BULL

Both sides have a point here — STIM's 6/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH 🎯 Target: $1.73 (-23.1%)

Spot @ $2.25

Altman Z of 0.2 and Debt/Equity of 2.94 sit alongside an FCF yield of -11.25% and ROIC of -35%, the weakest pillars in the RQD rating.

I respect the product at Neuronetics Inc., but the stock at $2.25 is a different story. Altman Z of 0.2 and Debt/Equity of 2.94 sit alongside an FCF yield of -11.25% and ROIC of -35%, the weakest pillars in the RQD rating.. FCF yield is -11.25% and RQD sits at 28/100 (E) — why pay up here when you can wait for next quarter's numbers?